Peer-reviewed veterinary case report
Pimobendan helps dogs with heart failure live longer and avoid lung
By Mizuno, Masashi et al.·Published in The Journal of veterinary medical science·2017·Japan Animal Specialty Medical Institute Inc., Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
- Species:
- dog
Plain-English summary
A group of dogs with congestive heart failure (CHF) caused by a heart valve issue were treated with a medication called pimobendan, either at a standard or low dose, alongside their usual treatments. The dogs receiving pimobendan lived longer than those on conventional therapy alone, with median survival times of 334 days for the standard dose and 277 days for the low dose, compared to just 136 days for the conventional group. Additionally, the standard dose of pimobendan significantly reduced the chances of pulmonary edema (fluid in the lungs) returning. This suggests that pimobendan can be an effective addition to treatment for dogs with CHF.
People also search for: dog congestive heart failure treatment · pimobendan for dogs · pulmonary edema in dogs · heart medication for dogs · myxomatous mitral valve disease in dogs
Abstract
The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD). Records of 197 client-owned dogs from 14 veterinary hospitals were included in this study. Dogs were administered conventional treatments with or without pimobendan. Sixty-four dogs received a standard dose of pimobendan (0.20-0.48 mg/kg every 12 hr (q12hr)), 49 dogs received a low dose of pimobendan (0.05-0.19 mg/kg q12hr), and 84 dogs received conventional therapy alone. Dogs in the standard-dose and low-dose pimobendan groups had significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P<0.001). The reoccurrence rate of pulmonary edema in the standard-dose group was significantly lower than in the low-dose and conventional groups (43%, 59% and 62%, respectively; P<0.05). Combination of pimobendan with a conventional treatment regimen significantly prolonged survival time after an initial episode of pulmonary edema in dogs with CHF caused by MMVD. There was no difference in survival between dogs administered standard and low doses of pimobendan, but pimobendan did prevent the reoccurrence of pulmonary edema in a dose-dependent manner.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27644192/